Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
10.1016/j.cellsig.2023.110689 Summary Keywords clinical transition, dual inhibitors, phosphodiesterase 10A, phosphodiesterase 1B, schizophrenia Citation Rautela J, Gaurav A, Nissapatorn V, Tan CK, Girol AP, Pereira MDL and Lee VS (2026) PDE1B and PDE10A as novel targets for schizophrenia: from molecular design and synthesis to therapeutic promise
The authors concluded that GHK-Cu accelerates wound healing and skin repair through coordinated effects on collagen and glycosaminoglycan turnover, modulation of metalloproteinase activity, attraction of immune and endothelial cells to injury sites, and restoration of replicative vitality in irradiated fibroblasts [1]
WGK 1 CAS No
ISO/IEC 17025
Utilizzato negli studi clinici che coinvolgono esseri umani Somministrato agli esseri umani come parte di un esperimento o indagine Fornito a un'altra parte per uso investigativo umano Perch scegliere GHK-Cu di CellPeptides
US$ 21.75
US$ 21.00
US$ 22.76
US$ 20.22
